Literature DB >> 25051177

Current compound coverage of the kinome.

Ye Hu1, Norbert Furtmann, Jürgen Bajorath.   

Abstract

Publicly available kinase inhibitors have been analyzed in detail. Nearly 19000 inhibitors have been identified with activity against 266 different kinases. Thus, about half of the human kinome is currently covered with active small molecules. The distribution of inhibitors across the kinome is uneven. Most available kinase inhibitors are likely to be type I inhibitors. By contrast, type II inhibitors are rare but usually have high potency. Kinase inhibitors generally display high scaffold diversity. Activity cliffs with an at least 100-fold difference in potency are only found for inhibitors of 106 kinases, which is partly due to only small numbers of compounds available for many kinases, in addition to scaffold diversity. Moreover, kinase inhibitors are less promiscuous than often thought. More than 70% of available inhibitors are only annotated with a single kinase activity, and only ∼1% of the inhibitors are active against five or more kinases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25051177     DOI: 10.1021/jm5008159

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.

Authors:  Johannes Rudolph; Yao Xiao; Arthur Pardi; Natalie G Ahn
Journal:  Biochemistry       Date:  2014-12-04       Impact factor: 3.162

2.  Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.

Authors:  Filip Miljković; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-12-02       Impact factor: 3.686

3.  Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes.

Authors:  Qian Zhao; Xiaohu Ouyang; Xiaobo Wan; Ketan S Gajiwala; John C Kath; Lyn H Jones; Alma L Burlingame; Jack Taunton
Journal:  J Am Chem Soc       Date:  2017-01-04       Impact factor: 15.419

4.  KLIFS: a structural kinase-ligand interaction database.

Authors:  Albert J Kooistra; Georgi K Kanev; Oscar P J van Linden; Rob Leurs; Iwan J P de Esch; Chris de Graaf
Journal:  Nucleic Acids Res       Date:  2015-10-22       Impact factor: 16.971

5.  Activation of RyR2 by class I kinase inhibitors.

Authors:  A D Chakraborty; L A Gonano; M L Munro; L J Smith; C Thekkedam; V Staudacher; A B Gamble; N Macquaide; A F Dulhunty; P P Jones
Journal:  Br J Pharmacol       Date:  2019-01-30       Impact factor: 8.739

6.  Differentiating Inhibitors of Closely Related Protein Kinases with Single- or Multi-Target Activity via Explainable Machine Learning and Feature Analysis.

Authors:  Christian Feldmann; Jürgen Bajorath
Journal:  Biomolecules       Date:  2022-04-08

7.  Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors.

Authors:  Anna Cichonska; Balaguru Ravikumar; Elina Parri; Sanna Timonen; Tapio Pahikkala; Antti Airola; Krister Wennerberg; Juho Rousu; Tero Aittokallio
Journal:  PLoS Comput Biol       Date:  2017-08-07       Impact factor: 4.475

8.  Effects of FGFR2 kinase activation loop dynamics on catalytic activity.

Authors:  Jerome M Karp; Samuel Sparks; David Cowburn
Journal:  PLoS Comput Biol       Date:  2017-02-02       Impact factor: 4.475

9.  Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases.

Authors:  Dilyana Dimova; Jürgen Bajorath
Journal:  Molecules       Date:  2017-05-03       Impact factor: 4.411

Review 10.  Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  Future Sci OA       Date:  2017-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.